Harmony Biosciences Holdings, Inc. (HRMY) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Harmony Biosciences Holdings, Inc. (HRMY) Bundle
Gain insight into your Harmony Biosciences Holdings, Inc. (HRMY) valuation analysis using our state-of-the-art DCF Calculator! This Excel template is preloaded with real HRMY data, enabling you to adjust forecasts and assumptions to accurately calculate the intrinsic value of Harmony Biosciences.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.0 | 159.7 | 305.4 | 437.9 | 582.0 | 971.2 | 1,620.7 | 2,704.5 | 4,513.0 | 7,531.0 |
| Revenue Growth, % | 0 | 2564.59 | 91.21 | 43.35 | 32.93 | 66.87 | 66.87 | 66.87 | 66.87 | 66.87 |
| EBITDA | -142.7 | 1.5 | 106.4 | 143.6 | 221.5 | 12.9 | 21.5 | 35.8 | 59.8 | 99.7 |
| EBITDA, % | -2380.22 | 0.94715 | 34.82 | 32.79 | 38.06 | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
| Depreciation | 3.2 | 10.2 | 18.8 | 23.4 | 24.4 | 146.9 | 245.2 | 409.2 | 682.8 | 1,139.4 |
| Depreciation, % | 53.54 | 6.41 | 6.17 | 5.34 | 4.19 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 |
| EBIT | -145.9 | -8.7 | 87.5 | 120.2 | 197.2 | -30.1 | -50.2 | -83.7 | -139.7 | -233.2 |
| EBIT, % | -2433.76 | -5.46 | 28.66 | 27.45 | 33.87 | -3.1 | -3.1 | -3.1 | -3.1 | -3.1 |
| Total Cash | 24.5 | 228.6 | 234.3 | 323.1 | 353.5 | 798.8 | 1,333.0 | 2,224.4 | 3,711.9 | 6,194.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.3 | 22.2 | 34.8 | 54.7 | 74.1 | 236.0 | 393.9 | 657.2 | 1,096.7 | 1,830.1 |
| Account Receivables, % | 70.98 | 13.88 | 11.41 | 12.5 | 12.74 | 24.3 | 24.3 | 24.3 | 24.3 | 24.3 |
| Inventories | 1.1 | 3.8 | 4.4 | 4.3 | 5.4 | 46.4 | 77.5 | 129.3 | 215.7 | 359.9 |
| Inventories, % | 18.15 | 2.39 | 1.45 | 0.98138 | 0.92144 | 4.78 | 4.78 | 4.78 | 4.78 | 4.78 |
| Accounts Payable | 6.4 | 2.6 | 1.0 | 3.8 | 17.7 | 205.6 | 343.1 | 572.5 | 955.3 | 1,594.1 |
| Accounts Payable, % | 106.09 | 1.6 | 0.32772 | 0.86467 | 3.05 | 21.17 | 21.17 | 21.17 | 21.17 | 21.17 |
| Capital Expenditure | -127.1 | -2.0 | -100.3 | -40.2 | -.3 | -278.4 | -464.6 | -775.2 | -1,293.6 | -2,158.7 |
| Capital Expenditure, % | -2120.92 | -1.25 | -32.84 | -9.17 | -0.05360622 | -28.66 | -28.66 | -28.66 | -28.66 | -28.66 |
| Tax Rate, % | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 | 25.69 |
| EBITAT | -151.7 | -12.2 | 80.9 | 208.3 | 146.5 | -28.1 | -46.8 | -78.2 | -130.5 | -217.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -274.7 | -28.5 | -15.4 | 174.6 | 164.0 | -174.6 | -317.6 | -530.0 | -884.4 | -1,475.7 |
| WACC, % | 8.44 | 8.44 | 8.36 | 8.44 | 8.17 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,476.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,505 | |||||||||
| Terminal Value | -23,618 | |||||||||
| Present Terminal Value | -15,799 | |||||||||
| Enterprise Value | -18,275 | |||||||||
| Net Debt | -118 | |||||||||
| Equity Value | -18,157 | |||||||||
| Diluted Shares Outstanding, MM | 60 | |||||||||
| Equity Value Per Share | -300.75 |
What You Will Get
- Real Harmony Biosciences Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Harmony Biosciences' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Data: Harmony Biosciences' historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: Observe Harmony Biosciences' intrinsic value recalculating instantly.
- Intuitive Visual Outputs: Dashboard charts illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance specialists.
How It Works
- Download the Template: Gain immediate access to the Excel-based HRMY DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically compute Harmony Biosciences' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial strategy.
Why Choose This Calculator for Harmony Biosciences (HRMY)?
- Accuracy: Utilizes real Harmony Biosciences financials for precise data.
- Flexibility: Tailored for users to easily adjust and experiment with inputs.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive interface, accessible even for those new to financial modeling.
Who Should Use Harmony Biosciences Holdings, Inc. (HRMY)?
- Investors: Make informed investment choices with cutting-edge insights into the biotech sector.
- Healthcare Analysts: Streamline your analysis with comprehensive data on Harmony's innovative therapies.
- Consultants: Effortlessly tailor reports and presentations to highlight HRMY's market potential.
- Biotech Enthusiasts: Enhance your knowledge of the industry by exploring Harmony's groundbreaking solutions.
- Educators and Students: Utilize it as a hands-on resource for courses focused on biotechnology and finance.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Harmony Biosciences historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Harmony Biosciences Holdings, Inc. (HRMY).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.